Transdermal therapeutic system for 5-aminolevulinic acid hydrochloride
The invention relates to a transdermal therapeutic system, comprising a back layer that is impermeable to an active ingredient, a polymer matrix containing the active ingredient, and a protective layer that can be pulled off, wherein 5-aminolevulinic acid hydrochloride is used as the active ingredient and the basic polymer of the polymer matrix is an adhesive polyacrylate. Said transdermal therapeutic system is suitable for diagnosing and treating preliminary stages of skin cancer, such as actinic keratosis, and oncological skin diseases.
1. A transdermal therapeutic system, comprising:
a back layer that is impermeable to an active ingredient;
an active ingredient-containing polymer matrix; and
a protective layer that can be pulled off;
wherein the polymer matrix consists of:
about 28% by weight of crystalline 5-aminolevulinic acid hydrochloride as the active ingredient; and
about 72% by weight of a non-crosslinked polyacrylate adhesive based on acrylic acid, 2-ethylhexyl acrylate, and methyl acrylate;
wherein the transdermal therapeutic system is a monolithic active ingredient-in-adhesive system; and
wherein the transdermal therapeutic system releases within about four hours, an amount of at least 3 mg 5-aminolevulinic acid hydrochloride.
2. The transdermal therapeutic system according to claim 1 ;
wherein 50% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride are larger than the layer thickness of the polymer matrix.
3. The transdermal therapeutic system according to claim 1 ;
wherein more than 99.9% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride are smaller than about 250 μm.
4. The transdermal therapeutic system according to claim 1 ;
wherein the polyacrylate has acid functionalities.
5. A method comprising:
utilizing the transdermal therapeutic system according to claim 1 as a therapeutic agent.
6. A method comprising:
utilizing the transdermal therapeutic system according to claim 1 for treating preliminary skin cancer stages.
7. A method comprising:
utilizing the transdermal therapeutic system according to claim 1 for diagnosing and treating preliminary skin cancer stages.
8. The transdermal therapeutic system according to claim 3 ;
wherein more than 99.9% of the crystals of the crystalline 5-aminolevulinic acid hydrochloride have a particle size of 90 to 160 μm.
9. The method according to claim 6 ;
wherein the skin cancer is selected from the group consisting of actinic keratosis and oncological skin diseases.
10. The method according to claim 7 ;
wherein the skin cancer is selected from the group consisting of actinic keratosis and oncological skin diseases.
11. The transdermal therapeutic system according to claim 1 ;
wherein the transdermal therapeutic system releases at least 35% of the 5-aminolevulinic acid hydrochloride within thirty minutes.
12. The transdermal therapeutic system according to claim 1 ;
wherein the polymer matrix consists of:
28% by weight of crystalline 5-aminolevulinic acid hydrochloride as the active ingredient; and
72% by weight of a non-crosslinked polyacrylate adhesive based on acrylic acid, 2-ethylhexyl acrylate, and methyl acrylate.